Effectiveness of nurse-led group CBT for hot flushes and night sweats in women with breast cancer: Results of the MENOS4 randomised controlled trial

Deborah Fenlon1 | Tom Maishman2 | Laura Day3 | Jacqueline Nuttall2 | Carl May3 | Mary Ellis2 | James Raftery4 | Lesley Turner2 | Jo Fields5 | Gareth Griffiths2 | Myra S. Hunter6

Abstract
Objective: Troublesome hot flushes and night sweats (HFNS) are experienced by many women after treatment for breast cancer, impacting significantly on sleep and quality of life. Cognitive behavioural therapy (CBT) is known to be effective for the alleviation of HFNS. However, it is not known if it can effectively be delivered by specialist nurses. We investigated whether group CBT, delivered by breast care nurses (BCNs), can reduce the impact of HFNS.

Methods: We recruited women with primary breast cancer following primary treatment with seven or more HFNS/week (including 4/10 or above on the HFNS problem rating scale), from six UK hospitals to an open, randomised, phase 3 effectiveness trial. Participants were randomised to Group CBT or usual care (UC). The primary endpoint was HFNS problem rating at 26 weeks after randomisation. Secondary outcomes included sleep, depression, anxiety and quality of life.

Results: Between 2017 and 2018, 130 participants were recruited (CBT:63, control:67). We found a 46% (6.9-3.7) reduction in the mean HFNS problem rating score from randomisation to 26 weeks in the CBT arm and a 15% (6.5-5.5) reduction in the UC arm (adjusted mean difference $-1.96$, CI $-3.68$ to $-0.23$, $P = .039$). Secondary outcomes, including frequency of HFNS, sleep, anxiety and depression all improved significantly.

Conclusion: Our results suggest that specialist nurses can be trained to deliver CBT effectively to alleviate troublesome menopausal hot flushes in women following breast cancer in the NHS setting.

Keywords
breast cancer, cancer, CBT, hot flushes, night sweats, oncology, specialist nurse
INTRODUCTION

Hot flushes and night sweats (HFNS) may be experienced by up to 85% of women after breast cancer,1 having a significant impact on sleep, quality of life and with social consequences on employment and personal relationships.2-4 HFNS tend to be worse in women who have been treated for breast cancer, largely because many breast cancer treatments are aimed at suppressing or opposing oestrogen, with HFNS being the natural consequence. Furthermore, oestrogen replacement is contraindicated in women with breast cancer.

The use of serotonin and norepinephrine reuptake inhibitors (SSRI and SNRIs), such as venlafaxine and citalopram, have been favoured as the best available treatment for hot flushes after breast cancer.5 These show moderate reductions in HFNS frequency but have little effect on quality of life measures; furthermore, they may be associated with unpleasant side effects, such as anorgasmia, anxiety, insomnia, restlessness and headaches, as well as having potential interactions with other medication, such as tamoxifen.5,6 Furthermore, many women prefer to employ non-medical alternatives following their breast cancer treatment.7 There are currently no consistent standard care pathways for HFNS in UK practice and few women are offered any effective management for this problem.8

There is evidence that cognitive behavioural therapy (CBT) is effective for the alleviation of HFNS in women. CBT for menopausal symptoms was developed by Hunter and colleagues9 and has been evaluated in several randomised controlled trials.10-13 The intervention draws on Hunter and Mann's14 theoretical model of HFNS, based on symptom perception, self-regulation and cognitive behavioural theories to explain women’s cognitive appraisal and behavioural reactions to symptoms. This model has been tested in a variety of settings and shows that women's beliefs drive the way that women experience HFNS and that their perception of HFNS as problematic can be altered by changes in beliefs and behaviours.15-17 (Figure 1). The combination of cognitive and behavioural changes can bring about reductions in the extent to which women view HFNS as problematic and interfering with their lives, as well as improvements in mood, sleep and quality of life.

Health professional-led group sessions provide a cost-effective solution and were positively viewed in the previous MENOS1 trial.11 Beyond HFNS, benefits of CBT, such as improvements in mood and quality of life, were found to be more pronounced for group CBT than with self-help CBT in a trial with well women.10 While it has been demonstrated that this is an effective intervention to help alleviate HFNS in women after breast cancer11,12 there are still large numbers of women suffering who do not have access to group CBT.8

There is an increasing awareness that new evidence is not always routinely incorporated into practice.18 In order to make this intervention available to women, it was hypothesised that this was most likely to happen if implemented by those health professionals who already provide interventions to support women throughout their breast cancer experience. Most women with breast cancer will see a breast care nurse (BCN), whose role it is to support women to cope with the consequences of their treatment. The delivery of BCN-led group CBT sessions may, therefore, be a feasible and cost-effective solution.

---

**FIGURE 1** A typical cognitive behavioural therapy vicious cycle of thoughts, feelings and behaviours when women have problematic hot flushes.
is some evidence that nurses can effectively deliver CBT for cancer patients; however, training nurses to deliver CBT for menopausal hot flushes according to the MENOS protocol has not yet been evaluated. We designed the MENOS 4 study to investigate whether breast care nurses can be trained to deliver CBT in an NHS context to effectively manage HFNS in women who have had breast cancer.

2 | METHODS

2.1 | Study design and participants

The MENOS4 study was a multi-centre phase III randomised controlled trial of BCN-delivered group CBT vs usual care (see trial protocol). The primary aim was to evaluate the effectiveness of BCN-led group CBT on reducing the impact of HFNS in women with breast cancer 26 weeks after randomisation. Secondary aims included: (a) impact on HFNS 9 weeks after randomisation; (b) frequency of HFNS at 9 and 26 weeks; (c) the level of fidelity of CBT when delivered by BCNs; (d) the effect of group CBT on quality of life (QoL) and other symptoms, for example, sleep, anxiety (e) the effect on women's hot flush beliefs and behaviours and (f) an estimate of the cost-effectiveness.

Recruitment took place in hospitals throughout England and Wales. We included females 16 years and older, with primary breast cancer or DCIS, who had completed primary treatment, experiencing seven or more HFNS/week, with an overall rating of 4/10 or above on the Hot Flush Problem Rating scale and the desire and ability to attend group sessions. Exclusion criteria were metastatic disease and male. All women provided written informed consent before enrolment and randomisation. Approval was gained from a UK Research Ethics Committee (16/SC/0364), and NHS R&D departments at participating sites. The study was sponsored by the University of Southampton and coordinated by the Southampton Clinical Trials Unit (SCTU). The trial is registered with International Standard Randomized Controlled Trial Number 12824632.

2.2 | Procedures

Potential participants were identified and recruited via: (a) identification at breast cancer follow-up clinics; (b) letter of invitation from research nurses to potential participants; (c) participant identification centres where potential participants could be referred to a research site; (d) leaflets and posters in clinics and local health and wellbeing events; (e) social media promotion strategies including through Breast Cancer Now, Breast Cancer Haven and Twitter.

2.3 | Randomisation

Once 12 to 16 eligible participants were recruited at each site, individual randomisation was conducted by an independent statistician, allocating participants in a 1:1 ratio, stratified by site, with fixed block size. Each site aimed to run two sequential groups of the intervention with 6 to 8 women per group.

2.4 | Intervention arm—CBT

The BCNs delivering the intervention were selected by sites and trained by a clinical psychologist (MSH) over 2 days, using the training manual to deliver the CBT intervention. The manual contains detailed session content; presentation slides and handouts. For full training details on training and a description of the CBT, see the protocol paper. Following training, the BCNs received ongoing supervision of their delivery of group CBT from the trainer by email or telephone as required. Intervention arm participants attended weekly group CBT sessions, lasting 90 minutes each, for 6 weeks, following the structured manual which included a psycho-education and the cognitive behavioural model; stress management; paced breathing; cognitive and behavioural strategies to improve wellbeing and for managing hot flushes, night sweats and sleep; and maintaining changes. A typical CBT vicious cycle of thoughts, feelings and behaviours that women with troublesome symptoms report is shown in Figure 1. The CBT, targeting the cognitive and behavioural elements, is described in full in the manual, which has PowerPoint slides, homework sheets and a paced breathing relaxation CD.

2.5 | Control arm

Usual care (UC) was standard NHS care at the site. Each site used their normal approach, which differed between sites, since there is no current UK standard of care. Women were generally given ad hoc advice about HFNS, typically, only if they raised the issue. For ethical reasons, participants in the usual care arm were offered a version of self-help CBT after the final assessment at week 26.

2.6 | Outcome measures

At baseline, demographic and clinical information were recorded. At both baseline, 9 weeks and 26 weeks after randomisation, we recorded the number of HFNS and bother related to HFNS using a 3-day diary card, hot flushes (HFNS Rating scale & HFNS Belief and Behaviour Scale), depression (patient health questionnaire [PHQ], general anxiety disorder (GAD-7), sleep (Pittsburgh Sleep Quality Index [PSQI]), impact of hot flushes on daily activities and overall QoL (Hot Flash Related Daily Interference Scale [HFRDIS]) and quality of life (EQ-5D-5 L - also collected on weeks 3 and 6 while on intervention). See protocol paper for full description.

The primary outcome measure was HFNS Problem Rating taken at 26 weeks after randomisation. This measure has been used...
in clinical trials and predicts QoL and help-seeking to a greater extent than HFNS frequency and is recommended as an appropriate outcome measure in trials of HFNS treatments.\textsuperscript{24,25} Problem rating and severity tend to be associated with each other—neither are strongly associated with frequency of HFNS.\textsuperscript{21,24} HFNS problem rating has good internal consistency (Cronbach $\alpha = 0.9$) and test-retest reliability ($r = 0.8$)\textsuperscript{24} and has been used successfully in previous MENOS studies.

Secondary outcomes included HFNS problem rating at 9 weeks, and HFNS frequency, beliefs about HFNS, the hot flash related daily interference scale (HFRDIS)\textsuperscript{26} quality of life, sleep, anxiety and depression measures at 9 and 26 weeks after randomisation. The original intention was to include FACT-ES to explore quality of life but this was withdrawn later to shorten the questionnaire and improve response rate. The Short Form Hot Flush Beliefs and Behaviours Scale (HFBBS) was used to collect information about beliefs and behaviours about hot flushes.\textsuperscript{27,28} Data were collected for health economic analysis using EQ5D\textsuperscript{29} and process evaluation based on Normalisation Process Theory.\textsuperscript{30} These data will be reported elsewhere. Serious adverse events were notified to SCTU at the 9-week questionnaire time-point and followed up accordingly with the research nurse and the participants’ GP.

2.7 | Adherence

Patient adherence to group CBT was measured by the number of sessions attended and the number of times that a participant reported practising relaxation/paced breathing each week. Where participants missed a session, the BCN covered the session by telephone (up to 30 minutes).

2.8 | Fidelity

All group sessions were audio recorded (with consent), and 17% were randomly selected, ensuring two sessions per site were selected. An independent psychologist, not involved in the training, rated the BCNs for their fidelity and adherence to the manual.

2.9 | Sample size

A difference of two points or more in the HFNS Problem Rating Scale is regarded as clinically relevant.\textsuperscript{11} To detect a two-point difference (SD 2.4; standardised effect size 0.8), in mean HFNS problem rating between arms, 90% power requires 64 participants in total, assuming a two-sided significance level of 0.05. Allowing for inflation factor of 1.49 (intraclass correlation 0.07; 8 participants per group),\textsuperscript{31} to adjust for expected clustering within groups, gave a minimum sample size of 96, increasing to 120 to allow for 20% loss to follow-up and for each site to run two groups.

2.10 | Statistical analysis

The difference in HFNS Problem Rating Scale between the two arms was tested using a linear mixed model, utilising fixed and random effects. The regression model compared HFNS problem rating between arms at follow-up, adjusting for baseline HFNS problem rating score, cohort and stratification factor (site). Greater precision of estimates was expected within therapy groups (clustering effect), so the therapist was fitted as a random effect for the partially nested data. Secondary outcomes at follow-up were analysed in a similar way. For secondary outcome models where residuals were not normally distributed and no sensible transformation could be utilised, quantile regression adjusting for baseline score, cohort and site was used. Repeated measures analyses were utilised to allow simultaneous modelling of the three outcome time points. Analyses were based on a modified intention-to-treat population (ie, excluding participants who contribute fewer than two items on the outcome measure). All analyses were conducted according to a pre-specified analysis plan using SAS v9.4 and approved by the trial team before completion of data collection. $P$ values less than 0.05 were regarded as significant for all analyses.

3 | RESULTS

Between February 2017 and January 2018, 130 women were recruited from six UK hospitals. Sixty-three women were allocated to group CBT and 67 to UC (see Figure S1). Three women (CBT:2 and UC:1) withdrew, resulting in study data available for 127 (CBT:61, UC:66). The baseline characteristics were well balanced between groups (Table 1). At the start of the trial, women were suffering a median of 58 (Inter Quartile Range [IQR] 35-84) flushes per week (CBT group) and 63 (IQR 28-91) (UC group) and a mean problem rating of 6.9 (SD 1.73) out of 10 (CBT group) and 6.5 (SD 2.13) (UC group).

3.1 | Treatment adherence

The group sessions included 5 to 9 participants (except one group of 3). Participant adherence to treatment was good: 45 (73.8%) of 61 participants who received CBT, attended at least four sessions. Of 68% (43/63) who answered the question, the majority practised paced breathing daily (60%), 21% 3 to 4 times a week, 14% 5 to 6 times, and 5% only 1 to 2 times. Of 67% (42/63) who answered the question, 17% used the relaxation CD daily, 12% 5 to 6 times/week, 36% 3 to 4 times/week, 29% 1 to 2 times/week and 6% not all.

3.2 | HFNS problem rating

For the primary endpoint—HFNS problem rating score at 26 weeks—we found a statistically significant difference between groups ($P = .039$), equivalent to a 46% (6.9-3.7) reduction in the HFNS
problem rating score in the CBT arm and a 15% (6.5-5.5) reduction in the UC arm (Table 2, Figure 2). We conducted pre-specified sensitivity analyses on the primary outcome at 26-weeks for group size and those women who only received 4 of the 6 sessions. The effect held for both analyses (Table 2).

### 3.3 HFNS frequency

We found a significant difference between groups in HFNS frequency at 26 weeks, with a 28% (58-42) reduction in HFNS incidence in the CBT group compared to an 11% (63-56) reduction in the UC group ($P = .010$). Similar results were found at 9 weeks ($P = .017$) (Table 3).

#### 3.4 Hot flash related daily interference scale (HFRDIS)

There was a significant difference in the Hot Flash Related Daily Interference Scale (HFRDIS) between groups at 26 weeks ($P < .0001$) and 9 weeks ($P < .0001$) (Table 3).

| TABLE 1 Demographics and clinical details |
|------------------------------------------|
|                                          |
| Site                                     |
|                                          |
| Luton and Dunstable                      | 12 (19.7%) | 11 (16.7%) |
| Royal Glamorgan Cardiff                  | 10 (16.4%) | 11 (16.7%) |
| Walsall Manor Hospital                   | 5 (8.2%)   | 6 (9.1%)   |
| Queen Alexandra Portsmouth               | 14 (23.0%) | 15 (22.7%) |
| York Teaching Hospital                   | 7 (11.5%)  | 8 (12.1%)  |
| Yeovil District Hospital                 | 13 (21.3%) | 15 (22.7%) |
| Age at baseline assessment (years; mean [SD]) | 53.5 (9.78) | 55.2 (10.19) |
| Mean BMI (kg/m²; SD)                     | 28.5 (4.61) | 28.1 (4.94) |
| Ethnicity White                          | 58 (96.7%) | 62 (95.4%) |
| Married/living with partner              | 43 (72.9%) | 54 (84.4%) |
| Educated 16+ years of age                | 38 (64.4%) | 30 (46.2%) |
| Employed                                 | 34 (56.7%) | 40 (60.6%) |
| Current smoker                           | 5 (8.5%)   | 5 (7.6%)   |
| Exercise                                 |
|                                          |
| Once a week or less                      | 27 (45.0%) | 22 (33.3%) |
| More than once a week                    | 33 (55.1%) | 44 (66.7%) |
| Alcohol consumption (units per week)     |
|                                          |
| >7                                       | 55 (91.7%) | 56 (84.8%) |
| 7+                                       | 5 (8.4%)   | 10 (15.1%) |
| Distance participant lives from the treatment centre (miles; median [IQR]) | 6.0 (4.0-10.0) | 6.0 (3.0-12.0) |
| Treatment history                        |
|                                          |
| Chemotherapy                             | 38 (62.3%) | 33 (50.0%) |
| Radiotherapy                             | 57 (93.4%) | 56 (84.8%) |
| Herceptin                                | 9 (15.8%)  | 6 (9.5%)   |
| Hysterectomy                             | 14 (23.0%) | 9 (13.6%)  |
| Bilateral oophorectomy                   | 9 (15.5%)  | 6 (9.1%)   |
| Time since last period (years; median [IQR]) | 4.0 (1.0-8.0) | 4.0 (1.0–8.0) |
| Taking endocrine treatment at baseline   | 55 (90.1%) | 65 (98.4%) |
| Taking a prescribed drug for HFNS at baseline | 18 (34.0%) | 18 (30.5%) |
| Baseline HFNS problem rating (mean [SD]) | 6.9 (1.73)  | 6.5 (2.13) |
| Baseline HFNS frequency (per week; mean [SD]) | 62.3 (32.21) | 67.1 (46.89) |

Abbreviations: CBT, cognitive behavioural therapy; HFNS, hot flushes and night sweats; IQR, Inter Quartile Range.
3.5 | Sleep, anxiety and depression

There was significant improvement in sleep quality at both 26 weeks \((P < .0001)\) and 9 weeks \((P < .0001)\) (Table 3). Anxiety and depression also both significantly improved at both 9 and 26 weeks (Table 3).

3.6 | Beliefs and behaviours about HFNS

Negative beliefs about HFNS improved for all subscales in the CBT group, as did positive coping behaviour; there was a significant improvement between group difference at both 9 and 26 weeks. (Table 3).

3.7 | Fidelity

CBT was delivered according to the treatment manual, with an average of 94% adherence. The majority (10/12) of BCNs adhered to >90% of the CBT topics, (range 75%-100%). The most frequent session aim not delivered was the practising of paced breathing; however, a review of relaxation and paced breathing was always conducted.

Eleven BCNs underwent the training (all female, aged 45-48 years). Four had prior experience of delivering group sessions and eight had received advanced communication skills training. Three had received training in counselling, only one had experience or

---

**TABLE 2** Hot flush and night sweats problem-rating scores

|                     | CBT mean (SD) | Usual care: mean (SD) | CBT vs usual care mean difference (95% CI; \(P\) value) |
|---------------------|--------------|-----------------------|-----------------------------------------------------|
| HFNS                |              |                       |                                                     |
| Baseline            | 6.9 (1.73)   | 6.5 (2.13)            |                                                     |
| 9 weeks             | 4.1 (2.01)   | 5.5 (2.61)            | \(-1.83 \text{ (} -2.53 \text{ to } -1.12; <.0001)\) |
| 26 weeks            | 3.7 (2.16)   | 5.5 (2.45)            | \(-1.96 \text{ (} -3.68 \text{ to } -0.23; .039)\)    |

| HFNS (excluding patients with <4 CBT sessions/ telephone calls) | CBT mean (SD) | Usual care: mean (SD) | CBT vs usual care mean difference (95% CI; \(P\) value) |
|-----------------------------------------------------------------|--------------|-----------------------|-----------------------------------------------------|
| Baseline            | 6.7 (1.73)   | 6.5 (2.13)            |                                                     |
| 9 weeks             | 3.7 (1.88)   | 5.5 (2.61)            | \(-2.11 \text{ (} -3.02 \text{ to } -1.20; .0018)\)  |
| 26 weeks            | 3.3 (1.86)   | 5.5 (2.45)            | \(-2.38 \text{ (} -3.21 \text{ to } -1.55; <.0001)\) |

| HFNS (excluding one cohort of two patients)                      | CBT mean (SD) | Usual care: mean (SD) | CBT vs usual care mean difference (95% CI; \(P\) value) |
|-----------------------------------------------------------------|--------------|-----------------------|-----------------------------------------------------|
| Baseline            | 6.9 (1.72)   | 6.5 (2.18)            |                                                     |
| 9 weeks             | 4.1 (2.02)   | 5.5 (2.69)            | \(-1.78 \text{ (} -2.52 \text{ to } -1.04; .0001)\)  |
| 26 weeks            | 3.7 (2.16)   | 5.5 (2.49)            | \(-1.89 \text{ (} -2.75 \text{ to } -1.03; .0001)\)  |

Abbreviations: CBT, cognitive behavioural therapy; HFNS, hot flushes and night sweats; IQR, Inter Quartile Range.

**FIGURE 2** Hot flushes and night sweats problem rating score vs time from randomisation (Usual care vs cognitive behavioural therapy)
### Table 3  Effect of treatment on hot flushes and night sweats and secondary measures

|                      | Mean (SD)                  | Adjusted mean diff 95% CI; P value |
|----------------------|----------------------------|-----------------------------------|
|                      | CBT                        | Usual care                        |                                 |
| **HFRDIS**           |                            |                                   |                                 |
| Baseline             | 57.8 (21.20)               | 51.8 (23.29)                      |                                 |
| 9 weeks              | 30.9 (22.79)               | 45.1 (24.90)                      | **−19.55**; **−27.20 to −11.91; <.0001** |
| 26 weeks             | 29.6 (25.23)               | 46.1 (24.83)                      | **−21.36**; **−29.79 to −12.94; <.0001** |
| **Depression (PHQ-9)** |                            |                                   |                                 |
| Baseline             | 18.9 (5.77)                | 17.7 (6.06)                       |                                 |
| 9 weeks              | 15.9 (5.37)                | 17.2 (5.51)                       | **−2.14**; **−3.61 to −0.66; .005** |
| **Sleep quality (Pittsburgh)** |             |                                   |                                 |
| Baseline             | 2.9 (0.83)                 | 2.9 (0.74)                        |                                 |
| 26 weeks             | 2.3 (0.78)                 | 2.9 (0.68)                        | **−0.57**; **−0.81 to −0.33; <.0001** |
| **Total HFNS frequency** |                            |                                   |                                 |
| Baseline             | 58.0 (35.0-84.0)           | 63.0 (28.0-91.0)                  |                                 |
| 9 weeks              | 38.5 (16.0-73.0)           | 49.0 (22.0-80.5)                  | **−13.41**; **−24.38 to −2.44; .017** |
| 26 weeks             | 42.0 (17.0-63.0)           | 56.0 (28.0-77.0)                  | **−20.22**; **−34.46 to −4.93; .010** |
| **Anxiety (GAD-7)**  |                            |                                   |                                 |
| Baseline             | 13.0 (10.5-16.0)           | 11.0 (8.0-15.0)                   |                                 |
| 9 weeks              | 10.0 (7.0-14.0)            | 12.0 (9.0-15.1)                   | **−1.54**; **−3.01 to −0.07; .041** |
| 26 weeks             | 11.0 (7.0-14.0)            | 12.0 (9.0-17.0)                   | **−2.14**; **−3.61 to −0.66; .005** |
| **Sleep quality (Pittsburgh)** |             |                                   |                                 |
| Baseline             | 3.0 (2.0-3.5)              | 3.0 (2.0-3.0)                     |                                 |
| 9 weeks              | 2.0 (2.0-3.0)              | 3.0 (3.0-3.0)                     | **−0.67**; **−0.94 to −0.39; <.0001** |
| **Depression (PHQ-9)** |                            |                                   |                                 |
| Baseline             | 18.0 (15.0-22.0)           | 16.0 (13.0-20.0)                  |                                 |
| 26 weeks             | 15.0 (12.0-18.0)           | 17.0 (12.5-20.5)                  | **−2.86**; **−4.73 to −0.98; .003** |
| **HFBBS (subscale 1)** |                            |                                   |                                 |
| Baseline             | 2.7 (1.66)                 | 2.6 (1.48)                        |                                 |
| 9 weeks              | 1.7 (1.44)                 | 2.4 (1.50)                        | **−0.84**; **−1.31 to −0.37; .0006** |
| 26 weeks             | 1.7 (1.46)                 | 2.2 (1.62)                        | **−0.71**; **−1.09 to −0.33; .0004** |
| **HFBBS (subscale 2)** |                            |                                   |                                 |
| Baseline             | 2.8 (1.14)                 | 2.7 (1.15)                        |                                 |
| 9 weeks              | 1.8 (1.43)                 | 2.6 (1.02)                        | **−0.96**; **−1.62 to −0.29; .013** |
| 26 weeks             | 1.7 (1.42)                 | 2.5 (1.09)                        | **−0.87**; **−1.32 to −0.41; .0003** |
| **HFBBS (subscale 3)** |                            |                                   |                                 |
| Baseline             | 2.8 (1.23)                 | 2.3 (1.08)                        |                                 |
| 9 weeks              | 1.4 (0.93)                 | 2.2 (1.28)                        | **−1.01**; **−1.38 to −0.64; <.0001** |
| 26 weeks             | 1.3 (1.23)                 | 2.0 (1.22)                        | **−0.96**; **−1.38 to −0.54; <.0001** |
| **HFBBS (subscale 5)** |                            |                                   |                                 |
| Baseline             | 1.9 (1.43)                 | 1.5 (1.43)                        |                                 |
| 26 weeks             | 1.3 (1.48)                 | 1.5 (1.41)                        | **−0.63**; **−1.88 to 0.61; .159** |
training in CBT. Nine BCNs completed pre- and post-questionnaires. The average confidence for skills to run group CBT (scale 1-10) was 5.3 before and 7.7 after training. Their views of how effective training would be were, on average, 6.7 pre- and 8.2 post-training. Their average confidence in using the CBT model with participants for stress and hot flushes increased from 5.2 before to 8.1.

4 | DISCUSSION

These findings support previous studies, which show that group CBT for HFNS is effective in helping women who have had breast cancer to manage troublesome HFNS.

4.1 | Clinical implications

For the first time, we provide evidence that this intervention can be delivered effectively by nurses in the NHS setting; previous trials have been led by a clinical psychologist. This intervention of group CBT, delivered by trained breast care nurses, was effective in reducing not only the extent to which HFNS was regarded as a problem by women, but other benefits included a reduction in the frequency of HFNS, improved sleep, reduced anxiety and depression and reduced impact on everyday life. Furthermore, the benefit immediately following the group intervention at 9 weeks was sustained at 26 weeks. Sensitivity analyses suggested that these effects were neither influenced by the cohort group, nor the individual delivering the intervention, which suggests that this intervention would be replicable across the NHS. The programme itself is easily transferable because it is manualised, and adherence to the manual was high. An implementation strategy needs to be developed and this intervention could potentially be delivered as part of a survivorship programme.

In contrast to serotonin and norepinephrine reuptake inhibitors, CBT resulted in statistically significant and lasting improvements in frequency and problem-rating of HFNS, as well as improved sleep, anxiety and depression.

4.2 | Study limitations

This study used a different quality of life measure to the MENOS1 trial, so direct comparisons could not be made. Nor did we collect potential adverse psychological effects from the intervention. Although we did not conduct a formal mediation analysis, we demonstrated changes in HFNS beliefs and behaviours—that is, cognitive appraisal and behavioural reactions—factors that have been found to mediate improvements in HFNS following this CBT protocol. These changes also support Hunter and Mann's cognitive model of HFNS. The results add to the evidence that CBT is a safe and effective intervention with specific benefits to HFNS compared to non-medical alternatives, such as mindfulness, yoga, acupuncture.

Further research might explore the broader implementation of the CBT intervention; for example, “training the trainer,” online learning, congress workshops, etc, that were not covered in this study.

5 | CONCLUSIONS

Our findings suggest that CBT is an important alternative to medication for women with troublesome hot flushes and night sweats following breast cancer treatment, and that this intervention can be delivered in practice by trained breast care nurses in the NHS, with significant benefit to patients to improve their health.

ACKNOWLEDGEMENTS

Breast Cancer Now commissioned MENOS4(2015CR_004). The commissioning board commented on study design, but no further part in management or analysis. Recruitment was supported by the research nurses and staff within the NIHR Clinical Research Network Cancer in England and Welsh equivalent. We thank Melanie Smith for conducting the fidelity assessment. We thank J. Haviland, L. Yao and P. Khambaita for advising on the original proposal and T. Rose, A. Galanopolou, J. Abab and E. Kirkpatrick for their contribution.
Finally, we thank the principal investigators and their colleagues for recruitment and treatment of patients.

CONFLICT OF INTEREST
M.S.H. developed the CBT programme and co-authored the CBT manual, but has no other financial support from pharmaceutical or private practice. D.F.: honorarium from Roche. All others have no conflicts of interest.

DATA AVAILABILITY STATEMENT
Data supporting the findings of this study will be made available on request from the corresponding author for approved data sharing requests. Anonymous data will be available for request from three months after publication, to researchers who provide a completed Data Sharing request form for the purpose of an approved proposal and if appropriate, signed a Data Sharing Agreement. The data are not publicly available due to privacy/ethical reasons.

ORCID
Deborah Fenlon https://orcid.org/0000-0001-7347-8919

REFERENCES
1. Gupta P, Sturdee D, Palin S, et al. Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric. 2006;9:49-58.
2. Fenlon DR, Rogers AE. The experience of hot flushes after breast cancer. Cancer Nurs. 2007;30(4):E19-E26.
3. Fenlon DR, Corner JL, Haviland J. Menopausal hot flushes after breast cancer. Eur J Cancer Care. 2009;18(2):140-148.
4. Hunter MS, Grunfeld EA, Mittal S, et al. Menopausal symptoms in women with breast cancer: prevalence and treatment preferences. Psychooncology. 2004;13:769-778.
5. Szabo RA, Marino JL, Hickey M. Managing menopausal symptoms after cancer. Climacteric. 2019;22(6):572-578. https://doi.org/10.1080/13697173.2019.1646718.
6. Santarsieri D, Schwartz TL. Antidepressant efficacy and side-effect burden: a quick guide for clinicians. Drugs Context. 2015;4:1-12.
7. Reece JC, Chan YF, Herbert J, Gralow J, Fann JR. Course of depression, mental health service utilization and treatment preferences in women receiving chemotherapy for breast cancer. Gen Hosp Psychiatry. 2013;35(4):376-381.
8. Fenlon D, Morgan A, Khambaita P, et al. Management of hot flushes in UK breast cancer patients: clinician and patient perspectives. J Psychosom Obstet Gynaecol. 2017;38(4):276-283.
9. Hunter MS. Cognitive behavioural interventions for the treatment of menopausal symptoms. Expert Rev Obstet Gynaecol. 2012;4:321-326.
10. Ayers B, Smith M, Hellier J, Mann E, Hunter MS. Effectiveness of group and self-help cognitive behaviour therapy to reduce problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. Menopause. 2012;19(7):749-759. https://doi.org/10.1097/gme.0b013e31823fe835.
11. Mann E, Smith MJ, Hellier J, Hamed H, Grunfeld B, Hunter MS. Efficacy of a cognitive behavioural intervention to treat menopausal symptoms following breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012;13(3):309-318.
12. Duijts SFA, van Beurden M, Oldenburg HSA, et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized controlled multicenter trial. J Clin Oncol. 2012;30(33):4124-4133.
13. Ateva V, van Leeuwen M, Kieffer JM, et al. Efficacy of internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Clin Oncol. 2019;37:809-822. https://doi.org/10.1200/JCO.18.00655.
14. Hunter MS, Mann E. A cognitive model of menopausal hot flushes and night sweats. J Psychosom Res. 2010;69(5):491-501.
15. Hunter MS, Chilcot J. Testing a cognitive model of menopausal hot flushes and night sweats. J Psychosom Res. 2013;74(4):307-312.
16. Chilcot J, Norton S, Hunter MS. Cognitive behaviour therapy for menopausal symptoms following breast cancer treatment: who benefits and how does it work? Maturitas. 2014;78(1):56-61.
17. Norton S, Chilcot J, Hunter MS. Cognitive behaviour therapy for menopausal symptoms (hot flushes and night sweats): moderators and mediators of treatment effects. Maturitas. 2014;21(6):574-578.
18. Eccles M, Grimshaw J, Foy R. Disseminating and implementing evidence-based practice. Clinical governance in primary care. London: CRC Press; 2018:75-88.
19. Espie CA, Fleming L, Cassidy J, et al. Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol. 2008;26(28):4651-4658.
20. Fenlon D, Nuttall J, May C, et al. MENOS4 trial: a multicentre randomised controlled trial (RCT) of a breast care nurse delivered cognitive behavioural therapy (CBT) intervention to reduce the impact of hot flushes in women with breast cancer: study protocol. BMC Womens Health. 2018;18(1):63.
21. Hunter MS, Nuttall J, Fenlon D. A comparison of three outcome measures of the impact of vasomotor symptoms on women’s lives. Climacteric. 2019;22(4):319-423.
22. Hunter M, Smith M. Managing hot flushes with group cognitive behaviour therapy: an evidence based treatment manual for health professionals. New York, NY: Routledge; 2014.
23. Carpenter JS, Rand KL. Modeling the hot flash experience in breast cancer survivors. Menopause. 2018;15(3):469-475.
24. Hunter MS, Liao KLM. A psychological analysis of menopausal hot flushes. Br J Clin Psychol. 1995;34:589-599.
25. Rand KL, Otte JL, Flockhart D, et al. Modeling hot flushes and quality of life in breast cancer survivors. Climacteric. 2011;14(1):171-180.
26. Carpenter JS. The hot flash related daily interference scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer. J Pain Symptom Manag. 2001;22(6):979-989.
27. Hunter MS, Ayers B, Smith M. 2011 the hot flush behavior scale: a measure of behavioral reactions to menopausal hot flushes and night sweats. Menopause. 2011;18(11):1178-1183.
28. Rendall MJ, Simmons LM, Hunter MS. The hot flush beliefs scale: a tool for assessing thoughts and beliefs associated with experience of menopausal hot flushes and night sweats. Maturitas. 2008;60:158-169.
29. Chisholm D, Knapp MRJ, Knudsen HC, et al. Client socio-demographic and service receipt inventory - European version: development of an instrument for international research. Br J Psychiatry. 2000;177(39):s28-s33. https://doi.org/10.1192/bjp.177.39.s28.
30. Murray E, Treweek S, Pope C, et al. Normalisation process theory: a framework for developing, evaluating and implementing complex interventions. BMC Med. 2010;8(1):63.
31. Wampold BE, Brown GS. Estimating variability in outcomes attributable to therapists: a naturalistic study of outcomes in managed care. J Consult Clin Psychol. 2005;73(5):914-923.
32. Rozental A, Kottorp A, Forsström D, et al. The negative effects of menopausal symptoms. Br J Psychiatry. 2019;215(2):167-170.
33. Carpenter, J., Gass, M.L., Maki, P.M., et al. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of the North American Menopause Society. *Menopause*. 2015; 22(11):1155-1172.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

---

**How to cite this article:** Fenlon D, Maishman T, Day L. et al. Effectiveness of nurse-led group CBT for hot flushes and night sweats in women with breast cancer: Results of the MENOS4 randomised controlled trial. *Psycho-Oncology*. 2020;29:1514–1523. [https://doi.org/10.1002/pon.5432](https://doi.org/10.1002/pon.5432)